Severe acute respiratory syndrome
Therapeutic area
Pulmonology
Rare disease
Yes
- Definition
- A viral respiratory infection caused by the SARS coronavirus. It is transmitted through close person-to-person contact. It is manifested with high fever, headache, dry cough and myalgias. It may progress to pneumonia and cause death.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Severe acute respiratory syndrome
- Therapeutic area
- Pulmonology
- severe acute respiratory syndrome
- SARS
- SARS coronavirus caused disease or disorder
- SARS coronavirus disease or disorder
- SARS coronavirus infectious disease
- acute respiratory coronavirus infection
- Disease mechanisms
- Acquired
- Severity
- Severe
- Infectious Disease
- Pulmonology
- MONDO ID
- MONDO:0005091
- Parent condition
- MONDO:0005087
Related records
Broader conditions (13)
- Acute disease
- Coronaviridae infectious disease
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Disease of primarily extrinsic mechanism
- Human disease
- Infectious disease
- Nidovirales infectious disease
- Orthocoronavirinae infectious disease
- Primary viral infectious disease
- Respiratory system disorder
- Viral infectious disease
Trials (363)
- '4C' Intervention to Reduce SARS-CoV-2 (Covid-19) Transmission
- A Clinical Evaluation of Pine Trees Health Test System Including the Pine Trees Health Reader and COVID-19 Test for Point-of-Care
- A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
- A Feasibility Study Using the CoronaCheck Device to Identify Incident Cases of SARS CoV-2 Covid-19
- A Longitudinal Study of COVID-19 Positive Patients Testing Nasal Swabs and Collecting Blood Samples for Research
- A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir / Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory Syndrome
- A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19
- A Phase III Clinical Trial of the Immunogenicity and Safety of the Gam-COVID-Vac Vaccine Against COVID-19 in the UAE
- A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to (SARS-CoV-2) COVID-19 Pandemic
- A Registry Study of COVID-19 Serologic and Virologic Testing to Accelerate Recovery and Transition
- A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19
- A Study of LY3127804 in Participants With COVID-19
- A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19
- A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)
- A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2
- A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19
- A Study To Evaluate The Performance of the Lucira Health All-In-One COVID-19 Test Kit vs Hologic Panther Fusion
- A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19
- A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
- A Systems Approach to Predict the Outcome of SARS-CoV-2 in the Population of a City; COVID-19
Approved drugs (5)
Drugs in development (102)
- Alteplase Phase 2
- Aluminum hydroxide Phase 1
- Anakinra Phase 3
- Ascorbic acid Phase 3
- Aspirin Phase 3
- Azilsartan Phase 3
- Azithromycin Phase 3
- Baloxavir marboxil Phase 3
- Baricitinib Phase 3
- Bemnifosbuvir Phase 3
- Bevacizumab Phase 3
- Bicalutamide Phase 3
- Budesonide Phase 3
- Camostat Phase 3
- Camostat mesilate Phase 3
- Candesartan Phase 3
- Cannabinol Phase 2
- Casirivimab Phase 3
- Chloroquine phosphate Phase 2
- Cholecalciferol Phase 3